Leiomyosarcoma - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leiomyosarcoma is a kind of cancer. It is aggressive & rare in nature. It affects supportive or connective human tissues. These tissues are cartilage, bones, muscles, fat, and blood muscles. Leiomyosarcoma is also known as LMS. Quite often, it is misinterpreted as leiomyoma. However, the latter is different. LMS actually constitutes five to ten percent of soft tissue cancers. Its wide prevalence drives the leiomyosarcoma market.

Leiomyosarcoma is very unpredictable. It could be latent for a long time and appear after many years. The cancer is resistant and generally does not respond to radiation therapeutics or chemo-treatments. Normally, patients recover only if the sarcoma or tumor is operated on successfully, alongside wide margins early, though small & stationary in situ. Factors actually responsible for leiomyosarcoma remain unidentified.

However, according to researchers, ecological & hereditary dangers are connected with the illness. Some hereditary conditions within families may potentially boost people’s chances of having the cancer. Yet, a direct connection is not seen. Majority of these patients expect lots of love, care, & support from their families and oncologists.

Oncologists are cancer specialists. They operate from various medical centers and are best equipped to handle such cases. Several local oncologists witness only one or more such incidences in their entire career. Majority of the sarcoma centers partner with local doctors to help their patients. When patients are diagnosed with the illness, the latter’s stage is determined and necessary actions are taken.

This is the key to their survival, with one treatment to another for different stages. The leiomyosarcoma market, with regards to therapeutic products, offers targeted drugs. These medicines are not conventional cytotoxic, but targeted to prevent cancerous cells from growing inside the body. Normally, these have mild side effects and are well-tolerated by patients.

Some of the indications of leiomysarcoma are abdominal pain, jaundice, enlarged liver, abdominal uneasiness, renal vein obstruction, kidney dysfunction, and leg swelling. However, other illnesses may also display similar symptoms. Thus, patients are advised to consult their doctors for proper diagnosis and respective treatments.

Surgery is the usually the first line of treatment for this cancer. Chemotherapy, radio-treatments, radiology therapeutics, immuno-therapeutics, and hormonal treatments are the other available alternatives.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Leiomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Leiomyosarcoma - Overview 7
Pipeline Products for Leiomyosarcoma - Comparative Analysis 8
Leiomyosarcoma - Therapeutics under Development by Companies 9
Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Leiomyosarcoma - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Leiomyosarcoma - Products under Development by Companies 14
Leiomyosarcoma - Products under Investigation by Universities/Institutes 15
Leiomyosarcoma - Companies Involved in Therapeutics Development 16
GlaxoSmithKline plc 16
Karyopharm Therapeutics, Inc. 17
Merck & Co., Inc. 18
Mirati Therapeutics Inc. 19
Novartis AG 20
Pharma Mar, S.A. 21
Leiomyosarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
everolimus - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
mocetinostat - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NOV-110501 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pazopanib hydrochloride - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pembrolizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
selinexor - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
trabectedin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Leiomyosarcoma - Recent Pipeline Updates 60
Leiomyosarcoma - Dormant Projects 83
Leiomyosarcoma - Discontinued Products 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
Number of Products under Development for Leiomyosarcoma, H1 2015 7
Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Leiomyosarcoma - Pipeline by GlaxoSmithKline plc, H1 2015 16
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17
Leiomyosarcoma - Pipeline by Merck & Co., Inc., H1 2015 18
Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H1 2015 19
Leiomyosarcoma - Pipeline by Novartis AG, H1 2015 20
Leiomyosarcoma - Pipeline by Pharma Mar, S.A., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Leiomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 60
Leiomyosarcoma - Dormant Projects, H1 2015 83
Leiomyosarcoma - Discontinued Products, H1 2015 84